Recent advances in the treatment of advanced renal cell carcinoma: Towards multidisciplinary personalized care

BJU International

Volumn 110, Issue 9, 2012, Pages 1289-1300

  Bex, Axel ^a   Gore, Martin ^c   Mulders, Peter ^b   Sternberg, Cora N ^d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

biomarkers; multidisciplinary care; RCC; renal cell carcinoma; targeted therapy

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TUMOR MARKER; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; KIDNEY METASTASIS; MEDICAL DECISION MAKING; MEMORIAL SLOAN KETTERING CANCER CENTER CRITERIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT CODING; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; SUBCLINICAL HYPOTHYROIDISM; THYROID DISEASE; TREATMENT SELECTION; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; PATIENT CARE TEAM; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867742783     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11100.x     Document Type: Article

References (88)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917
2. Motzer RJ, Bander NH, Nanus DM,. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75
3. Antonelli A, Cozzoli A, Zani D, et al,. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007; 99: 296-300
4. Coppin C, Le L, Porzsolt F, et al,. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008; (4:2): CD006017
5. Escudier B, Kataja V,. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v137-v139
6. Ljungberg B, Cowan N, Hanbury DC, et al,. Guidelines on renal cell carcinoma. Eur Ass Urol 2010. Available at: http://www.uroweb.org/?id= 218&gid=4. Accessed March 2012
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer v.2. 2010. Available at: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed March 2012
8. ClinicalTrials.gov. Search term: axitinib. 2011. Available at: http://www.clinicaltrials.gov/ct2/results?term=axitinib. Accessed 17 November 2011
9. ClinicalTrials.gov. Search term: tivozanib. 2011. Available at: http://www.clinicaltrials.gov/ct2/results?term=tivozanib. Accessed 17 November 2011
10. Escudier B, Eisen T, Stadler WM, et al,. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-8
11. Escudier B, Bellmunt J, Negrier S, et al,. Phase III trial of bevacizumab plus Interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-50
12. Hudes G, Carducci M, Tomczak P, et al,. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81
13. Motzer RJ, Hutson TE, Tomczak P, et al,. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90
14. Motzer RJ, Escudier B, Oudard S, et al,. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65
15. Rini BI, Halabi S, Rosenberg JE, et al,. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-43
16. Sternberg CN, Davis ID, Mardiak J, et al,. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8
17. Sternberg CN, Hawkins RE, Szczylik C, et al,. Randomized, double blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC): final overall survival (OS) results. Oral presentation at the 35th European Society of Medical Oncology Congress, Milan, Italy. 2010
18. Rini BI, Halabi S, Rosenberg JE, et al,. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8
19. Escudier B, Pluzanska A, Koralewski P, et al,. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11
20. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24
21. Rini BI, Flaherty K,. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 2008; 26: 543-9
22. Rini BI, Atkins MB,. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000
23. Larkin J, Gore M,. Is advanced renal cell carcinoma becoming a chronic disease? Lancet 2010; 376: 574-5
24. Rini BI, Wilding G, Hudes G, et al,. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4462-8
25. Rini BI, Escudier B, Tomczak P, et al,. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011; 29 (Suppl.): Abstract 4503
26. Vickers MM, Choueiri TK, Rogers M, et al,. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010; 76: 430-4
27. Weikert S, Kempkensteffen C, Zimmerman K, et al,. Sequential use of temsirolimus (TEM) in patients with metastatic renal cell carcinoma (mRCC): safety and efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment. 25th Annual European Association of Urology Congress. 2010, Abstract 95
28. Oudard S,. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res 2010; 30: 5223-5
29. Rini BI, Hutson TE, Elson P, et al,. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. 2010. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=73&abstractID=30062. Accessed March 2012. ASCO 2010 Genitourinary Cancers Symposium (Abstract 319)
30. ClinicalTrials.gov. A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib sunitinib versus Sunitinib followed by followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma. 2011. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00732914?term=NCT00732914&rank=1. Accessed 17 November 2011
31. ClinicalTrials.gov. A randomised double-blind cross-over patient preference study of Pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01064310?term=NCT01064310&rank=1. Accessed 17 November 2011
32. ClinicalTrials.gov. A Phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1). 2011. Available at: http://www. clinicaltrials.gov/ct2/show/NCT01030783?term=NCT01030783&rank=1. Accessed 17 November 2011
33. ClinicalTrials.gov. Axitinib (AG-013736) for the treatment of metastatic renal cell cancer. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00920816?term=NCT00920816&rank=1. Accessed 17 November 2011
34. ClinicalTrials.gov. A randomized trial of temsirolimus versus sorafenib as second-line therapy in patients with advanced renal cell carcinoma who have failed first-line sunitinib therapy. 2011. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00474786?term=NCT00474786&rank=1. Accessed 17 November 2011
35. ClinicalTrials.gov. An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as First-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00903175?term=NCT00903175&rank=1. Accessed 17 November 2011
36. ClinicalTrials.gov. Sequential two-agent assessment in renal cell carcinoma therapy: the START trial. 2011. Available at: http://www. clinicaltrials.gov/ct2/show/NCT01217931?term=NCT01217931&rank=1. Accessed 17 November 2011
37. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED,. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-6
38. Choueiri TK, Xie W, Kollmannsberger C, et al,. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011; 185: 60-6
39. Logan T, McDermott D, Dutcher J, et al,. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. American Society for Clinical Oncology 2009 Genitourinary Cancers Symposium 2009; Abstract 281
40. ClinicalTrials.gov. Randomized phase III trial evaluating the importance of nephrectomy in patients presenting with metastatic renal cell carcinoma treated with sunitinib. 2011. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00930033?term=NCT00930033&rank=1. Accessed 17 November 2011
41. ClinicalTrials.gov. Randomized phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01099423?term=NCT01099423&rank=1. Accessed 17 November 2011
42. Abel EJ, Culp SH, Tannir NM, et al,. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011; 59: 10-5
43. Bex A, Jonasch E, Kirkali Z, et al,. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 2010; 58: 819-28
44. Hellenthal NJ, Underwood W, Penetrante R, et al,. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010; 184: 859-64
45. ClinicalTrials.gov. A phase II study of pazopanib to enable partial nephrectomy. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01158521?term=NCT01158521&rank=1. Accessed 17 November 2011
46. ClinicalTrials.gov. Sunitinib treatment of renal adjuvant cancer (S-TRAC): a randomized double blind phase 3 study of adjuvant sunitinib VS. placebo in subjects at high risk of recurrent RCC. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00375674?term=NCT00375674&rank=1. Accessed 17 November 2011
47. ClinicalTrials.gov. ASSURE: adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma. 2011. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT00326898?term=NCT00326898&rank=1. Accessed 17 November 2011
48. ClinicalTrials.gov. SORCE: a phase III randomised double-blind study comparing sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00492258?term=NCT00492258&rank=1. Accessed 17 November 2011
49. ClinicalTrials.gov. EVEREST: everolimus for renal cancer ensuing surgical therapy, A phase III study. 2011. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT01120249?term=NCT01120249&rank=1. Accessed 17 November 2011
50. ClinicalTrials.gov. A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01235962?term= NCT01235962&rank=1. Accessed 17 November 2011
51. Pfizer I. SUTENT. Summary of product characteristics; January 2011. 2011. Available at: http://www.medicines.org.uk/EMC/medicine/18531/SPC/SUTENT+12. 5mg%2c+25mg%2c+37.5mg+and+50mg+Hard+Capsules/. Accessed March 2012
52. Bayer Heathcare AG. Sorafenib, summary of product characteristics; December 2010. 2010. Available at: http://www.medicines.org.uk/EMC/medicine/ 18520/SPC/Nexavar+200mg+film-coated+tablets/. Accessed March 2012
53. Roche Products Ltd. Avastin, summary of product characteristics; January 2011. 2011. Available at: http://www.medicines.org.uk/EMC/medicine/15748/SPC/ Avastin+25mg+ml+concentrate+for+solution+for+infusion/. Accessed March 2012
54. pazopanib), Summary of product characteristics; June 2010. 2011. Available at: http://www.medicines.org.uk/EMC/ medicine/23148/SPC/Votrient+200+mg+and+400+mg+film+coated+tablets/. Accessed March 2012
55. Powles T, Kayani I, Blank C, et al,. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011; 5: 1041-7
56. Jonasch E, Wood CG, Matin SF, et al,. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4076-81
57. Xu CF, Bing NX, Ball HA, et al,. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011; 29: 2557-64
58. Tazi EM, Essadi I, Tazi MF, Ahellal Y, M'rabti H, Errihani H,. Advanced treatments in non-clear renal cell carcinoma. Urol J 2011; 8: 1-11
59. Dutcher JP, de SP, McDermott D, et al,. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26: 202-9
60. Gore ME, Szczylik C, Porta C, et al,. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63
61. Stadler WM, Figlin RA, McDermott DF, et al,. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-80
62. ClinicalTrials.gov. To compare the anti-tumor activity of everolimus and sunitinib in subjects with mRCC with non-clear cell pathology. 2011. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01108445?term= NCT01108445&rank=1. Accessed 17 November 2011
63. Bruyere F, Hovens CM, Marson MN, et al,. VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol 2010; 184: 1273-8
64. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X,. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010; 31: 1805-12
65. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al,. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12: 1143-50
66. Jonasch E, Corn P, Pagliaro LC, et al,. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116: 57-65
67. Klatte T, Seligson DB, LaRochelle J, et al,. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 894-900
68. Mues AC, Landman J,. Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines. Curr Opin Urol 2010; 20: 105-10
69. Ball HA, Xu C, Sternberg CN, et al,. Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma. J Clin Oncol 2010; 28: Abstract 4520
70. Tran HT, Liu Y, Lin Y, et al,. Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. J Clin Oncol 2010; 28: Abstract 4522
71. Rixe O, Dutcher J, Motzer R, et al,. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 2009; 25: Abstract 5045
72. Rini BI, Cohen DP, Lu D, et al,. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. American Socierty for Clinical Oncology 2010 Genitourinary Cancers Symposium 2010; Abstract 312
73. Schmidinger M, Vogl UM, Bojic M, et al,. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2010; 117: 534-44
74. Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS,. The role of molecular markers in the staging of renal cell carcinoma. BJU Int 2000; 99: 1208-11
75. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96
76. Patil S, Figlin RA, Hutson TE, et al,. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011; 22: 295-300
77. Heng DY, Xie W, Regan MM, et al,. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9
78. Eisenhauer EA, Therasse P, Bogaerts J, et al,. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47
79. Thiam R, Fournier LS, Trinquart L, et al,. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010; 21: 936-40
80. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V,. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010; 9: 15-9
81. van der Veldt AAM, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E,. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102: 803-9
82. Notohamiprodjo M, Sourbron S, Staehler M, et al,. Measuring perfusion and permeability in renal cell carcinoma with dynamic contrast-enhanced MRI: a pilot study. J Magn Reson Imaging 2010; 31: 490-501
83. Lassau N, Koscielny S, Albiges L, et al,. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010; 16: 1216-25
84. Pedrosa I, Alsop DC, Rofsky NM,. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 2009; 115 (Suppl.): 2334-45
85. Schmidinger M, Bellmunt J,. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010; 36: 416-24
86. Bhojani N, Jeldres C, Patard JJ, et al,. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917-30
87. Ravaud A,. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 2009; 20 (Suppl. 1): i7-i12
88. Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A,. Optimising the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2010; 28: 856-64